Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study
ZA Seman, F Ahid, NR Kamaluddin, ENM Sahid… - BMC Research …, 2024 - Springer
Objective Mutational analysis of BCR:: ABL1 kinase domain (KD) is a crucial component of
clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or …
clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or …
A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience
G Datta, SP Verma, AK Tripathi - Indian Journal of Hematology and Blood …, 2024 - Springer
CML is a commonly diagnosed myeloproliferative neoplasm in India. Tyrosine kinase
inhibitors (TKIs) are the current standard of care for management of CML. Mutations in …
inhibitors (TKIs) are the current standard of care for management of CML. Mutations in …
Chronic Myeloid Leukemia in Resource Limited Settings: Treatment Free Remission and Tyrosine Kinase Resistance
SK Gupta, S Sharma - Indian Journal of Hematology and Blood …, 2024 - Springer
Sarma et al.,[6] retrospectively analyzed the outcomes in 38 CML patients, with median age
of 44 (24–73) years at diagnosis, who had achieved deep molecular responses (DMR) and …
of 44 (24–73) years at diagnosis, who had achieved deep molecular responses (DMR) and …